224 related articles for article (PubMed ID: 6332854)
1. Specific killing of lymphocytes that cause experimental autoimmune myasthenia gravis by ricin toxin-acetylcholine receptor conjugates.
Killen JA; Lindstrom JM
J Immunol; 1984 Nov; 133(5):2549-53. PubMed ID: 6332854
[TBL] [Abstract][Full Text] [Related]
2. Selective in vitro inhibition of an antibody response to purified acetylcholine receptor by using antigen-ricin A chain immunotoxin.
Olsberg CA; Mikiten TM; Krolick KA
J Immunol; 1985 Nov; 135(5):3062-7. PubMed ID: 3876374
[TBL] [Abstract][Full Text] [Related]
3. Specificity of the T cell immune response to acetylcholine receptor in experimental autoimmune myasthenia gravis. Response to subunits and synthetic peptides.
Fujii Y; Lindstrom J
J Immunol; 1988 Mar; 140(6):1830-7. PubMed ID: 2450133
[TBL] [Abstract][Full Text] [Related]
4. Oral administration of acetylcholine receptor: effects on experimental myasthenia gravis.
Okumura S; McIntosh K; Drachman DB
Ann Neurol; 1994 Nov; 36(5):704-13. PubMed ID: 7979216
[TBL] [Abstract][Full Text] [Related]
5. T cell reactivity to acetylcholine receptor in rats orally tolerized against experimental autoimmune myasthenia gravis.
Wang ZY; Qiao J; Melms A; Link H
Cell Immunol; 1993 Dec; 152(2):394-404. PubMed ID: 8258147
[TBL] [Abstract][Full Text] [Related]
6. Regulation of antibody production by helper T cell clones in experimental autoimmune myasthenia gravis.
Fujii Y; Lindstrom J
J Immunol; 1988 Nov; 141(10):3361-9. PubMed ID: 2972772
[TBL] [Abstract][Full Text] [Related]
7. The limitation of IL-10-exposed dendritic cells in the treatment of experimental autoimmune myasthenia gravis and myasthenia gravis.
Xiao BG; Duan RS; Zhu WH; Lu CZ
Cell Immunol; 2006 Jun; 241(2):95-101. PubMed ID: 17005165
[TBL] [Abstract][Full Text] [Related]
8. Induction of apoptosis in activated T cell blasts by suppressive macrophages: a possible immunotherapeutic approach for treatment of autoimmune disease.
McIntosh KR; Drachman DB
Cell Immunol; 1999 Apr; 193(1):24-35. PubMed ID: 10202110
[TBL] [Abstract][Full Text] [Related]
9. On the initial trigger of myasthenia gravis and suppression of the disease by antibodies against the MHC peptide region involved in the presentation of a pathogenic T-cell epitope.
Atassi MZ; Oshima M; Deitiker P
Crit Rev Immunol; 2001; 21(1-3):1-27. PubMed ID: 11642597
[TBL] [Abstract][Full Text] [Related]
10. Suppression of experimental myasthenia gravis by a B-cell epitope-free recombinant acetylcholine receptor.
Yi HJ; Chae CS; So JS; Tzartos SJ; Souroujon MC; Fuchs S; Im SH
Mol Immunol; 2008 Nov; 46(1):192-201. PubMed ID: 18799218
[TBL] [Abstract][Full Text] [Related]
11. Depletion of CD8+ T cells suppresses the development of experimental autoimmune myasthenia gravis in Lewis rats.
Zhang GX; Ma CG; Xiao BG; Bakhiet M; Link H; Olsson T
Eur J Immunol; 1995 May; 25(5):1191-8. PubMed ID: 7774622
[TBL] [Abstract][Full Text] [Related]
12. Immunosuppression and induction of anergy by CTLA4Ig in vitro: effects on cellular and antibody responses of lymphocytes from rats with experimental autoimmune myasthenia gravis.
McIntosh KR; Linsley PS; Drachman DB
Cell Immunol; 1995 Nov; 166(1):103-12. PubMed ID: 7585970
[TBL] [Abstract][Full Text] [Related]
13. Selective in vitro inhibition of an antibody response to purified acetylcholine receptor by using anti-idiotypic antibodies coupled to the A chain of ricin.
DeShambo RM; Krolick KA
J Immunol; 1986 Nov; 137(10):3135-9. PubMed ID: 3490511
[TBL] [Abstract][Full Text] [Related]
14. B-T lymphocyte interactions in experimental autoimmune myasthenia gravis: autoantibody mediated up-regulation of the response of acetylcholine receptor-specific T lymphocytes.
Zhang Y; Tzartos S
Immunology; 1992 Dec; 77(4):571-6. PubMed ID: 1283599
[TBL] [Abstract][Full Text] [Related]
15. A 17-Mer self-peptide of acetylcholine receptor binds to B cell MHC class II, activates helper T cells, and stimulates autoantibody production and electrophysiologic signs of myasthenia gravis.
Yoshikawa H; Lambert EH; Walser-Kuntz DR; Yasukawa Y; McCormick DJ; Lennon VA
J Immunol; 1997 Aug; 159(3):1570-7. PubMed ID: 9233656
[TBL] [Abstract][Full Text] [Related]
16. The role of B-cells in experimental myasthenia gravis in mice.
Wang HB; Li H; He B; Bakheit M; Levi M; Wahren B; Berglöf A; Sandstedt K; Link H; Shi FD
Biomed Pharmacother; 1999 Jun; 53(5-6):227-33. PubMed ID: 10424244
[TBL] [Abstract][Full Text] [Related]
17. Clonotypic analysis of anti-acetylcholine receptor antibodies from experimental autoimmune myasthenia gravis-sensitive Lewis rats and experimental autoimmune myasthenia gravis-resistant Wistar Furth rats.
Zoda T; Yeh TM; Krolick KA
J Immunol; 1991 Jan; 146(2):663-70. PubMed ID: 1987281
[TBL] [Abstract][Full Text] [Related]
18. Combined short-term immunotherapy for experimental autoimmune myasthenia gravis.
Pestronk A; Drachman DB; Teoh R; Adams RN
Ann Neurol; 1983 Aug; 14(2):235-41. PubMed ID: 6354071
[TBL] [Abstract][Full Text] [Related]
19. TCR gene usage in experimental autoimmune myasthenia gravis pathogenesis. Usage of multiple TCRBV genes in the H-2b strains.
Wu B; Shenoy M; Goluszko E; Kaul R; Christadoss P
J Immunol; 1995 Apr; 154(7):3603-10. PubMed ID: 7897239
[TBL] [Abstract][Full Text] [Related]
20. Protective potential of experimental autoimmune myasthenia gravis in Lewis rats by IL-10-modified dendritic cells.
Duan RS; Adikari SB; Huang YM; Link H; Xiao BG
Neurobiol Dis; 2004 Jul; 16(2):461-7. PubMed ID: 15193302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
